A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck but in patients with recurrent or metastatic disease, EGFR targeting agents have displayed modest efficacy. Vascular endothelial growth factor (VEGF) mediated angiogenesis ha...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Cohen, Ezra EW, Davis, Darren W., Karrison, Theodore G, Seiwert, Tanguy Y., Wong, Stuart J., Nattam, Sreenivasa, Kozloff, Mark F., Clark, Joseph I., Yan, Duen-Hwa, Liu, Wen, Pierce, Carolyn, Dancey, Janet E, Stenson, Kerstin, Blair, Elizabeth, Dekker, Allison, Vokes, Everett E
Формат: Artigo
Язык:Inglês
Опубликовано: 2009
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768532/
https://ncbi.nlm.nih.gov/pubmed/19201650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70002-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы